The global infertility drugs market size was valued at US$ 3,699.8 million in the year 2023 and is estimated to reach US$ 6,814.68 million by 2033. This market is projected to expand at a CAGR of 6.3% during the analysis period. The increased prevalence of infertility is expected to boost the demand for infertility drugs. Women and men are equally affected by infertility.
Female infertility can be caused by factors such as growing older, polycystic ovarian syndrome (PCOS), obesity, and miscarriages, while male infertility can be caused by factors such as erectile dysfunction, low sperm count, abnormal sperm, etc. Researchers at the BGU developed a new treatment that stimulates telomerase expression and re-elongates the telomeres to protect cells.
For treating infertility, market players are introducing novel medications. In the current instance, Oxolife is developing the first-in-class product candidate OXO-001, which is designed to enhance the binding of embryos to the inner lining of the uterus by increasing binding. Moreover, the United States-based biopharmaceutical company Ferring Pharmaceuticals recently launched its novel fertility treatment, Trisequens, for women.
Developing such products addresses a medical need that affects women around the world undergoing assisted reproduction because there is no substitute for improving the endometrium's conditions for embryo implantation.
Infertility medicines are expected to contribute positively to the market as well as the presence of a variety of products for treating these conditions. For example, In-vitro fertilization (IVF) treatments, which involve fertilizing an egg outside of the body, are becoming more commonplace and are expected to drive market growth.
Infertility problems are caused by hormonal imbalance, polycystic ovarian disease, and weight issues caused by sedentary lifestyles. Therefore, the market is likely to grow over the forecast period as sedentary lifestyles become increasingly popular. The market growth may likely be hindered by rigid regulatory frameworks for product approval and high-priced patented products.
| Attributes | Details |
|---|---|
| Infertility Drugs Market Value (2023) | US$ 3,699.8 million |
| Infertility Drugs Market Expected Value (2033) | US$ 6,814.68 million |
| Infertility Drugs Market Projected CAGR (2023 to 2033) | 6.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global infertility drugs market expanded at 4.69% CAGR over the past 10 years. The market is expected to expand at a CAGR of close to 6.3% over the forthcoming decade. Due to the disruptions in the supply chain caused by the pandemic and the delay in delivering essential products needed to manufacture infertility drugs, the market for infertility drugs suffered. Additionally, fertility treatments were suspended or delayed across the globe during the pandemic, which also hampered market growth.
According to a study published by the National Library of Medicine in April 2021, ‘Suspension of fertility treatment during the pandemic: views, emotional reactions and psychological distress among women undergoing fertility treatment,’ fertility treatments were suspended during the initial phase of the pandemic. In such cases, it is evident that the market experienced slow growth during the pandemic.
| Historical CAGR (2016 to 2022) | 4.69% |
|---|---|
| Historical Market Value (2022) | US$ 3,480 million |
| Forecast CAGR | 6.3% |
The World Health Organization states that infertility affects millions of people of reproductive age worldwide. Globally, 48 million couples and 186 million individuals suffer from infertility. An infertility condition can be caused by male, female, or a combination of male and female factors, or it may be unexplained.
Infertility rates have been associated with environmental and lifestyle factors such as smoking, excessive alcohol consumption, obesity, and exposure to environmental pollutants for both women and men. This continues to be the primary reason why infertility drugs are so popular.
Infertility treatments and In-vitro fertilization (IVF) procedures often involve fertility medications, which prepare the body for treatment and increase the chance of eggs being released from the ovaries.
The infertility treatment space may continue to advance. This is due to decreased fertility rates, an increase in fertility clinics globally, technological advances, and public-private partnerships. All these factors are expected to shape the infertility drugs market.
Governments around the world have taken several initiatives to provide insurance coverage for treatment for infertility patients. For instance, in the United Kingdom, the National Health Service (NHS) covers the cost of some infertility treatments. Also in Canada, provincial health insurance plans cover the cost of assisted reproductive technologies for eligible patients. Moreover, a recent initiative announced by the Ministry of Health, Labor, and Welfare (MHLW) in March 2022 increased patients’ access to treatment by lowering the cost by 70% and increasing prescription rates.
Principal Consultant
Infertility drugs market growth is hampered by the side effects shown by the drugs, such as headaches, upper respiratory tract infections, abnormal bleeding or spotting, vomiting, injection site pain, and Ovarian Hyperstimulation Syndrome (OHSS).
According to a study published in NCBI in 2016, up to 10% to 20% of women who consume infertility drugs can develop mild OHSS, which usually resolves on its own without treatment. Severe cases occur in about one percent of patients.
There is also a possibility that the increased adoption rate of effective alternatives to medications may negatively impact the growth of the market. According to a research article published in Reproductive Biomedicine, 2.5 million IVF procedures are performed every year globally. There is a high threat of substitutes during the forecast period since most European countries offer full funding for several IVF procedures.
With a revenue share of 40.1% in 2023, the gonadotropins segment dominated the infertility drugs market and is expected to grow rapidly over the forecast period. Due to the high cost of products and their increased efficacy, some of the most commonly used gonadotropins to treat infertility patients include Gonal-F, Follitism, Menopur, and Bravelle.
The high efficacy associated with gonadotropins may attract a wider target population and expand revenue sources. Injections of chorionic gonadotropin without insurance, cost around US$ 397.83, while injections with insurance cost nearly US$ 304.76 per injection.
A phase 3 clinical trial was initiated by Bharat Serums and Vaccines Limited in March 2022. The trial was designed to evaluate the safety and effectiveness of Recombinant Human Follicle Stimulating Hormone 900 IU among women aged 20 to 39. In addition, QL1012 is currently being tested for ovarian stimulation in a phase 3 clinical trial conducted by Qilu Pharmaceutical Co., Ltd. As such, the launch of gonadotropins may continue to drive the industry at a high growth rate over the forecast period.
According to the market report, women dominated the market for infertility drugs in 2023 with a revenue share of 71.3%. This dominance was due in part to the wide availability of infertility drugs for women.
The women’s segment is expected to accelerate over the forecast period. This is due to the disease burden at reproductive age and the adoption of sedentary lifestyles, which interfere with ovulation.
An increasing prevalence of thyroid disorders and breast cancer, which require more radiation exposure, is the leading reason for infertility among women. This results in a dramatic decrease in fertility rates. Smoking and alcohol consumption are increasing, as are many illnesses like PCOS and uterine fibroids, causing an increase in demand.
According to an article, the prevalence of Polycystic Ovarian Syndrome (PCOS) in 2020 is estimated to range from 2.2% to 48.0% in many countries, including the United States, China, India, and Australia, among others. Therefore, the growth in prescriptions for drugs and the rising awareness of this condition among women is predicted to fuel the market.
According to the launch and rapid uptake of multiple infertility medicines, North America dominated the overall infertility drugs market by 35% in 2023. Research activities in the area of infertility are expected to create new opportunities for the region. Moreover, with women's hectic lifestyles and increased stress levels, North America is expected to dominate the world's infertility drug market during the projected period.
This dominance is primarily the result of rising menopausal illnesses, urinary infections, thyroid problems, endometriosis, and other conditions caused by these conditions. Over 5 million women of reproductive age are affected by PCOS, according to a study published by the Centers for Disease Control and Prevention (CDC).
Since the fertility rate in Canada was low in 2020, fewer babies were born in the country, according to Statistics Canada's report published in May 2022. As a result, such factors are expected to lead to an increase in the sale of infertility drugs in this region, thus boosting the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In the United States, oligozoospermia, varicocele, diabetes, and other diseases are on the rise, pushing the region's revenue share. As a result of improved healthcare infrastructure and an increased count of reproductive endocrinologists, the market for infertility drugs has expanded.
The United States' dominant position in the worldwide market is projected to be enhanced by government spending on women's healthcare awareness, an increase in geriatric women, and early product releases. The increasing rate of infertility and PCOS cases in the United States is driving the growth of the infertility drugs market.
This is due to a concentration of market players or manufacturers, acquisitions and partnerships among major players, and an increase in the number of cases of infertility and PCOS.
PCOS, one of the most common causes of female infertility in the United States, is estimated to affect around 6.0% to 12.0% of women of reproductive age annually, as reported by the Centers for Disease Control and Prevention (CDC) in March 2020. The market in the United States is likely to grow considerably because of such instances.
A market value of US$ 385.5 million is projected for the German market for infertility drugs by the year 2033. This results in Germany dominating the European Infertility Drugs Market in 2023. During the estimated period, Germany is projected to dominate the global market for infertility treatment drugs for women.
The ripeness rate of females in Germany was less than 2% in 2019, according to Eurostat. As a result of the high level of development in the healthcare industry, a high rate of infertility diagnosis and treatment, and a significant share of the market held by Germany in 2023.
Over the forecast period, India is projected to grow at a rate of 4.8%. Several key players in the market have participated in strategic initiatives to develop and commercialize effective infertility medicinal products to treat patients, which have contributed to the growth of the region.
According to the Ministry of Health, Labor, and Welfare (MHLW), 12 drugs were approved by the Ministry for the treatment of extra infertility in September 2022, including Novartis AG's Letrozole and Pfizer's Cabaser. This approval was expected to increase the market for novel drugs in India.
A generic form of Dydrogesterone tablets was developed and launched by Mankind Pharma in June 2022 in India to treat pregnancy-related complications. As a result of the launch, the infertility treatment market was expected to grow. This drug is equivalent to Abbott Duphaston tablets.
A new player in the fertility drugs market introduces novel products and forms alliances, collaborations, and partnerships. To accelerate innovation, digitization, and development in fertility treatment, CooperSurgical, a pioneer in women's healthcare solutions, established a multi-year strategic partnership with Virtus Health, a primary global provider of assisted reproductive services, in December 2021.
In June 2021, Hamilton Thorne Ltd. launched initiatives to help patients with fertility, including those who require egg, sperm, or embryo donations, emphasizing digitalization, cryogenics, and reproductive genetics. In the United States and Europe, GYNEMED GM501, a ready-to-use device designed for washing and handling human embryos and oocytes, has been approved by the United States FDA.
Several key players dominate the global infertility drugs market, which is moderately competitive. A competitive landscape analysis includes some international and local companies that hold the market share and are well known, such as Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, and Novartis AG.
The strategy of mergers, acquisitions, investments, expansions of capacity, and plant turnarounds by major manufacturers, is further strengthening the market player presence and helping them in staying ahead of the competition.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ million for Value and MT for Volume |
| Key Regions Covered | North America; Latin America; Europe; The Middle East and Africa; East Asia |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom, Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, and South Africa |
| Key Segments Covered | Drug Class, End User, Distribution Channel, Region |
| Key Companies Profiled | Abbott Laboratories; Bayer AG, Novartis AG; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceuticals Industries Ltd.; Sanofi S.A.; Ferring Holdings SA; Organon & Co.; Mankind Pharma Ltd. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is estimated to acquire US$ 3,699.8 million in 2023.
The increased prevalence of lifestyle disorders is the primary factor.
The United States accounts for the dominant market share.
Increased adoption of various infertility procedures creates opportunities.
A high level of development in the healthcare industry drives the market.
1. Executive Summary | Infertility Drugs Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Gonadotrophins
5.3.2. Aromatase Inhibitors
5.3.3. Selective Estrogen Receptor Modulators (SERMs)
5.3.4. Biguanides
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Male
6.3.2. Female
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By End User
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By End User
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By End User
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By End User
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom (UK)
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By End User
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By End User
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By End User
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By End User
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By End User
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By End User
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By End User
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By End User
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By End User
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By End User
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By End User
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By End User
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By End User
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By End User
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By End User
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By End User
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By End User
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By End User
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By End User
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By End User
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By End User
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By End User
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By End User
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By End User
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By End User
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By End User
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By End User
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By End User
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By End User
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By End User
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By End User
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By End User
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Merck & Co., Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Ferring B.V.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Organon Group of Companies
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Abbott
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Novartis AG
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Bayer AG
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Pfizer Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Mankind Pharma
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Teva Pharmaceutical Industries LTD.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Sanofi
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Infertility Drugs Market
